Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab +/- Chemotherapy in Advanced ESCC Responders
NCT04654403Phase 2Unknown
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Jan 2022
- Primary completion
- May 2022
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of camrelizumab in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: Duration of Response up to 12 months. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT04654403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04654403.